Formation of oligonucleotide adducts in pharmaceutical formulations

Pharmaceutical Development and Technology

Volumn 10, Issue 2, 2005, Pages 283-290

  Krotz, Achim H ^a   Gaus, Hans ^a   Hardee, Gregory E ^a  

^a ISIS PHARMACEUTICALS   (United States)

Author keywords

Adduct; Advanced glycation; Antisense; Chemical stability; Excipients; Formulation; Lipid; Oligonucleotides

Indexed keywords

ALICAFORSEN; ANTISENSE OLIGONUCLEOTIDE; DEOXYGUANOSINE DERIVATIVE; EXCIPIENT; GLYCEROL; NUCLEOSIDE; OLIGONUCLEOTIDE; PROPYLENE GLYCOL; TRIACYLGLYCEROL;

AQUEOUS SOLUTION; ARTICLE; COVALENT BOND; DNA ADDUCT; DRUG DOSAGE FORM; DRUG FORMULATION; DRUG STRUCTURE; GLYCATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; NUCLEAR MAGNETIC RESONANCE; PREFORMULATION; PRIORITY JOURNAL; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY;

CHEMISTRY, PHARMACEUTICAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DNA ADDUCTS; DRUG INCOMPATIBILITY; DRUG STABILITY; INDICATORS AND REAGENTS; MAGNETIC RESONANCE SPECTROSCOPY; MASS SPECTROMETRY; OINTMENTS; OLIGONUCLEOTIDES; QUALITY CONTROL; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION;

EID: 18744376294     PISSN: 10837450     EISSN: None     Source Type: Journal    
DOI: 10.1081/PDT-200054464     Document Type: Article

References (23)

1. Crooke, S.T. Progress in antisense technology: the end of the beginning. Methods Enzymol. 2000, 313, 3-45.
2. Crooke, S.T. Basic principles of antisense technology. In Antisense Drug Technology: Principles, Strategies, and Applications; Marcel Dekker: New York, 2001.
3. Holmlund, J.T. Applying antisense technology: affinitak and other antisense oligonucleotides in clinical development. Ann. N.Y. Acad. Sci. 2003, 1002, 244-251 (Therapeutic Oligonucleotides).
4. Dean, N.M.; Bennett, C.F. Antisense oligonucleotide-based therapeutics for cancer. Oncogene 2003, 22, 9087-9096.
5. Sorbera, L.A.; Leeson, P.A.; Bayes, M. Pegabtanib sodium: treatment of age-related macular degeneration treatment of diabetic retinopathy anti-VEGF aptamer. Drugs Future 2002, 27, 841-845.
6. Klasa, R.J.; Gillum, A.M.; Klem, R.E.; Frankel, S.R. Oblimersen Bcl-2 antisense: facilitating apoptosis in anticancer treatment. Antisense Nucleic Acid Drug Dev. 2002, 12, 193-213.
7. Wallace, D.J.; Tumlin, J.A. LJP 394 (abetimus sodium, Riquent) in the management of systemic lupus erythematosus. Lupus 2004, 13, 323-327.
8. Ravichandran, L.V.; Dean, N.M.; Marcusson, E.G. As research tool, antisense oligonucleotides are widely used in functional genomics and target validation. Use of antisense oligonucleotides in functional genomics and target validation. Oligonucleotides 2004, 14, 49-64.
9. Yu, R.Z.; Su, J.Q.; Grundy, J.S.; Geary, R.S.; Sewell, K.L.; Dorr, A.; Levin, A.A. Prediction of clinical responses in a simulated phase III trial of Crohn's patients administered the antisense phosphorothioate oligonucleotide ISIS 2302: comparison of proposed dosing regimens. Antisense Nucleic Acid Drug Dev. 2003, 13, 57-66.
10. Mehta, R.C.; Stecker, K.K.; Cooper, S.R.; Templin, M.V.; Tsai, Y.J.; Condon, T.P.; Bennett, C.F.; Hardee, G.E. Intercellular adhesion molecule-1 suppression in skin by topical delivery of antisense oligonucleotides. J. Invest. Dermatol. 2000, 115, 805-812.
11. International conference on harmonization; revised guidance on Q3B(R) impurities in new drug products; availability. Fed. Regist. 2003, 68 (220), 64628-64629.
12. Griffey, R.H.; Greig, M.J.; Gaus, H.J.; Liu, K.; Monteith, D.; Winniman, M.; Cummins, L.L. Characterization of oligonucleotide metabolism in vivo via liquid chromatography/electrospry tandem mass spectrometry with a quadrupole ion trap mass spectrometer. J. Mass Spectrom. 1997, 32, 305-313.
13. Krotz, A.H.; Mehta, R.C.; Hardee, G.E. Peroxide-mediated desulfurization of phosphorothioate oligonucleotides and its prevention. J. Pharm. Sci. 2005, 94, 341-352.
14. Chung, F.L.; Roy, K.R.; Hecht, S.S. A study of reactions of α,β-unsaturated carbonyl compounds with deoxyguanosine. J. Org. Chem. 1988, 53, 14-17.
15. Segal, A.; Fedyk, J.; Melchionne, S.; Seidman, I. The isolation and characterization of 2-carboxyethyl adducts following in vitro reaction of acrylic acid with calf thymus DNA and bioassay of acrylic acid in female Hsd: (ICR)Br mice. Chem.-Biol. Interact. 1987, 61, 189-197.
16. 2-alkylguanines. Biochemistry 1969, 8, 238-245.
17. Basu, A.K.; O'Hara, S.M.; Valladier, P.; Stone, K.; Mols, O.; Marnett, L.J. Identification of adducts formed by reaction of guanine nucleosides with malondialdehyde and structurally related aldehydes. Chem. Res. Toxicol. 1988, 1, 53-59.
18. Nissl, J.; Ochs, S.; Severin, T. Reaction of guanosine with glucose, ribose, and glucose 6-phosphate. Carbohydr. Res. 1996, 289, 55-65.
19. Seidel, W.; Pischetsrieder, M. Reaction of guanosine with glucose under oxidative conditions. Bioorg. Med. Chem. Lett. 1998, & 2017-2022.
20. Ochs, S.; Severin, T. Reaction of 2&-deoxyguanosine with glyceraldehyde. Liebigs Ann. Chem. 1994, 851-853.
21. 2-(1-carboxyethyl)guanine (CEG) as a guanine advanced glycosylation end product. Biochemistry 1995, 34, 648-655.
22. 2-(1-carboxymethyl)guanine (CMG) as a guanine advanced glycation end product. Bioorg. Med. Chem. Lett. 1998, 8, 2109-2110.
23. Grynberg, H.; Jamuszkiewicz, H. Deterioration of distilled glycerol during storage. Badawczych Przemyslu Spozywczego 1958, 8, 45-54.